37
1 The Novozymes Tick Trial 2012 Angelo Verzoni, MMCRI Vector-borne Disease Lab

The Novozymes Tick Trial 2012

Embed Size (px)

Citation preview

Page 1: The Novozymes Tick Trial 2012

1

The Novozymes Tick Trial 2012

Angelo Verzoni, MMCRI Vector-borne Disease Lab

Page 2: The Novozymes Tick Trial 2012

Photos: Vector-borne Disease Lab 2

MMCRI Vector-borne Disease Lab

Page 3: The Novozymes Tick Trial 2012

3

BackgroundI. scapularis, Lyme disease and controlling ticks

Page 4: The Novozymes Tick Trial 2012

Photos: Vector-borne Disease Lab and Monmouth County Mosquito Commission; Graphics: Microsoft Office 4

Ixodes scapularis

I. scapularis, or the deer tick, is the vector for Lyme and other potentially harmful diseases in humans and animals.

In the last two decades, the deer tick has become prevalent in Maine.

Page 5: The Novozymes Tick Trial 2012

Graphics: Vector-borne Disease Lab 5

I. scapularis in Maine

1989

1994

2009

Page 6: The Novozymes Tick Trial 2012

Graphics: Vector-borne Disease Lab 6

Lyme Disease in Maine

2009

2008

2007

2006

2005

2004

Page 7: The Novozymes Tick Trial 2012

Photo: Georgia Southern University 7

Lyme Disease

Lyme borreliosis, or Lyme disease, occurs after an infected deer tick has attached and fed for at least 24 hours.

Borrelia burgdorferi, a spirochetal bacteria, is the main cause of Lyme disease.

Fluorescing Bb spirochete

20 μm

Page 8: The Novozymes Tick Trial 2012

Photos: Vector-borne Disease Lab and Wikipedia 8

Symptoms of Lyme disease include an erythema migrans rash, fever, fatigue, headache, chills, muscle and joint pain and swollen lymph nodes.

Lyme disease is treated with antibiotics. The EM rash

Lyme Disease Symptoms and Treatment

Page 9: The Novozymes Tick Trial 2012

Photo: Microsoft Office 9

Lyme Disease Vaccine

A Lyme disease vaccine for humans (LYMErix) was approved by the FDA in 1998.

But the vaccine’s developer, GlaxoSmithKline, pulled it from the U.S. market in 2002 amidst negative media coverage and financial hardship.

Lyme disease vaccines are available for dogs.

Page 10: The Novozymes Tick Trial 2012

10

How do we control deer ticks?

Pesticides Insecticides ▪Acaricides

Page 11: The Novozymes Tick Trial 2012

Graphics: Wikipedia 11

Bifenthrin

Bifenthrin is a synthetic pyrethroid that acts as a neurotoxin and can be used to control a number of arthropods.

It inhibits the closing of sodium channels and is toxic to humans and non-target animals like bees and fish.

Page 12: The Novozymes Tick Trial 2012

12

Eco-Exempt IC2

Eco-Exempt IC2 is a botanical acaricide containing rosemary oil, peppermint oil, wintergreen oil, mineral oil and vanillin.

It blocks the octopamine neurotransmitter receptors in invertebrates.

It is not known to harm mammals, birds and fish since they lack these receptors.

Page 13: The Novozymes Tick Trial 2012

13

Bifenthrin vs. Eco-Exempt IC2A 2009 study by the VBDL compared

the two acaricides in their ability to control deer ticks.

The study found that IC2 was nearly as effective in killing deer ticks as bifenthrin and had only a temporary impact on non-target, ground insects and no impact on bees.

However, IC2 was observed to be moderately phytotoxic.

Page 14: The Novozymes Tick Trial 2012

14

The Project Novozymes, Met52, methods, results, conclusion and discussion

Page 15: The Novozymes Tick Trial 2012

Photo: Novozymes Biologicals, Inc. 15

What is Novozymes?

Novozymes is an international bio-technology corporation.

They have developed a formulation of Metarhizium anisopliae Strain F-52 (Met52) to kill ticks and other pests.

Page 16: The Novozymes Tick Trial 2012

16

What is Met52?

Met52 is a contact bio-insecticide.M. anisopliae Strain F-52 is a

naturally occurring, entomopathogenic soil fungus.

Page 17: The Novozymes Tick Trial 2012

Graphics: Novozymes Biologicals, Inc. 17

How does Met52 work?

Page 18: The Novozymes Tick Trial 2012

Graphics: Novozymes Biologicals, Inc. 18

How does Met52 work?

Page 19: The Novozymes Tick Trial 2012

Photos: Ray Young, Novozymes 19

How is Met52 applied?

Met52 is applied by way of a high-pressure spray.

Page 20: The Novozymes Tick Trial 2012

20

Our Role

Along with 24 other study sites, and in cooperation with Atlantic Pest Solutions, the Vector-borne Disease Lab elected to participate in a trial of Met52.

The objective of the study was to evaluate the effectiveness of Met52 to reduce deer ticks.

Page 21: The Novozymes Tick Trial 2012

21

Previous Literature on M. anisopliae

A study published in the Journal of Medical Entomology showed that exposure to M. anisopliae resulted in 96% deer tick mortality in a laboratory setting and 53% mortality in a field setting. The study concluded that M. anisopliae is highly pathogenic to adult deer ticks.

(Benjamin et al. 2002)

Page 22: The Novozymes Tick Trial 2012

22

Previous Literature on M. anisopliae

Another study published in the Journal of Medical Entomology concluded that M. anisopliae not only kills deer ticks but reduces their body mass and “fitness” too.

(Hornbostel et al. 2004)

Page 23: The Novozymes Tick Trial 2012

23

Experimental Set-up

21 plots were established in Arundel.

Seven plots were designated as control plots, and 14 plots were designated as treatment plots.

Page 24: The Novozymes Tick Trial 2012

24

Experimental Procedure

Tick flagging consisted of dragging a piece of corduroy through the brush and leaf litter for five minutes, checking for ticks after each minute.

Page 25: The Novozymes Tick Trial 2012

25

Results

The control plots yielded adult and nymphal deer tick means consistent with stage seasonality, while the treatment plots yielded no adult or nymphal deer ticks two weeks post spray.

Overall, Met52 reduced deer ticks by 80-100%.

Page 26: The Novozymes Tick Trial 2012

Graphics: Novozymes Biologicals, Inc. 26

I. scapularis Stage Seasonality

Page 27: The Novozymes Tick Trial 2012

27

Response of Adult Deer Ticks to Multiple Sprays of Met52

0.0

0.5

1.0

1.5

2.0

2.5

3.0

Me

an

# o

f T

ick

s

Control

Treatment

Met52 Spray #1

Met52 Spray #2 Met52 Spray #3

Page 28: The Novozymes Tick Trial 2012

28

Response of Nymphal Deer Ticks to Multiple Sprays of Met52

0.0

0.5

1.0

1.5

2.0

2.5

Me

an

# o

f T

ick

s

Control

Treatment

Met52 Spray #1

Met52 Spray #2 Met52 Spray #3

Page 29: The Novozymes Tick Trial 2012

29

Response of Adult Deer Ticks to a One-time Spray of Met52 on Jun 8

0

0.2

0.4

0.6

0.8

1

1.2

1.4

1.6

1.8

Mea

n #

of

Tic

ks

Control

Treatment

Met52 Spray

Page 30: The Novozymes Tick Trial 2012

30

Response of Nymphal Deer Ticks to a One-time Spray of Met52 on Jun 8

0

0.2

0.4

0.6

0.8

1

1.2

1.4

1.6

Me

an

# o

f T

ick

s

Control

Treatment

Met52 Spray

Page 31: The Novozymes Tick Trial 2012

31

% Reduction = 100 (Yc-Yt)/Yc

Reduction of Deer Ticks by Multiple Sprays of Met52

84

100

0

10

20

30

40

50

60

70

80

90

100

% Reduction of Adults % Reduction of Nymphs

% R

ed

ucti

on

Page 32: The Novozymes Tick Trial 2012

32

% Reduction = 100 (Yc-Yt)/Yc

Reduction of Deer Ticks by One Spray of Met52

9391

0

10

20

30

40

50

60

70

80

90

100

% Reduction of Adults % Reduction of Nymphs

% R

ed

ucti

on

Page 33: The Novozymes Tick Trial 2012

Lab Experiment

Control a I. scap.Treated a I. scap.

Treated a I. scap. (Close-up)

Page 34: The Novozymes Tick Trial 2012

34

Conclusion

Met52 effectively reduces deer ticks. It is slightly less effective than

synthetic acaricides but comparable to botanical ones.

It is an effective biological alternative to synthetic and botanical acaricides.

Page 35: The Novozymes Tick Trial 2012

35

Discussion

Although Met52 is naturally occurring, its effects on non-target species and the environment should be evaluated in further studies.

Page 36: The Novozymes Tick Trial 2012

36

Acknowledgements

Thank you to MMCRI, Liz Bergst and Dr. Jeong Yoon

Thank you to VBDL: Dr. Robert Smith, Dr. Peter Rand, Susan Elias, Chuck Lubelczyk, Leticia Smith, Eleanor Lacombe, Linda Turcotte and Ally Boyington.

And a special thanks to Ray Young, Novozymes and Atlantic Pest Solutions for their involvement in the project.

Page 37: The Novozymes Tick Trial 2012

37

Paper Citations

Benjamin, Michael A. et al. “Laboratory and Field Evalulation of the Entomopathogenic Fungus Metarhizium anisopliae (Deuteromycetes) for Controlling Questing Adult Ixodes scapularis (Acari: Ixodidae).” Journal of Medical Entomology. 2002.

Bharadwaj, Anuja and Kirby C. Stafford III. “Evaluation of Metarhizium anisopliae Strain F52 (Hypocreales: Clavicipitaceae) for Control of Ixodes scapularis (Acari: Ixodidae).” Journal of Medical Entomology. 2010.

Hornbostel, Victoria L. et al. “Sublethal Effects of Metarhizium anisopliae (Deuteromycetes) on Engorged Larval, Nymphal, and Adult Ixodes scapularis (Acari: Ixodidae).” Journal of Medical Entomology. 2004.

Pourseyed, S.H. et al. “Metarhizium anisopliae (Ascomycota: Hypocreales): An effective alternative to chemical acaricides against different developmental stages of fowl tick Argus persicus (Acari: Argasidae).” Journal of Veterinary Parasitology. 2010.